Anti-CDKN2A/p16INK4a antibody [EPR1473] - C-terminal (Ab108349)

推荐稀释比例

• IHC-P1/100 For unpurified use at 1/250 - 1/500. Perform heat-mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
• WB1/2000 For unpurified use at 1/1000 - 1/10000.
• Flow Cyt (Intra)1/270 - 1/500 For unpurified use at 1/100 - 1/500. ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody.
• IP1/30 For unpurified use at 1/10 - 1/100.

Anti-CDKN2A/p16INK4a antibody [EPR1473] - C-terminal (ab108349) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in Flow Cyt (Intra), IHC-P, IP and WB. Anti-CDKN2A/p16INK4a antibody [EPR1473] - C-terminal (ab108349) was first used in a scientific publication in 2013 and has been cited over 192 times in peer reviewed journals. It's performance in Western Blot and IHC in human samples is trusted by the scientific community. Abcam's high quality manufacturing and validation processes ensure Anti-CDKN2A/p16INK4a antibody [EPR1473] - C-terminal (ab108349) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility. The specificity of Anti-CDKN2A/p16INK4a antibody [EPR1473] - C-terminal (ab108349) has been confirmed by Western Blot testing in CDKN2A/p16INK4a knockout HEK-293T cells. Anti-CDKN2A/p16INK4a antibody [EPR1473] - C-terminal (ab108349) has 6 independent reviews from customers. Anti-CDKN2A/p16INK4a antibody [EPR1473] - C-terminal (ab108349) specifically detects CDKN2A/p16INK4a (UniProt ID: P42771; Molecular weight: 17kDa) and is sold in a convenient trial size to enable initial testing (20 µL) and larger sizes for subsequent scaling up experiments (100 µL and 1 mL). Conjugation-ready, carrier free format available for antibody clone EPR1473 - ab186932. Antibody clone EPR1473 is also available pre-conjugated to a variety of labels for your convenience - Alexa Fluor ® 647, PE ( ab192054, ab209579 ). CDKN2A, encoding the tumor suppressor protein p16INK4a, plays a crucial role in regulating the cell cycle by inhibiting cyclin-dependent kinases, thereby preventing uncontrolled cell proliferation. Mutations or deletions in CDKN2A are frequently associated with various cancers, including melanoma, pancreatic cancer and head and neck squamous cell carcinoma. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents. What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies.